of our a growth quarter Today accelerating positioning proprietary growth. business our products the With financial the restructuring line, the potential discuss we're and driven this and top of of for for streams, our addition I'll revenue XXXX, XXXX by our announced Rich. you, implications profitability long-term new morning, financial Thank billion-dollar the the updates upcoming expectations. third toward to and results
XXXX of adjusting but financial more third to fully overview revisions improved I'll we financial in commercial remaining financial an a are highlights start the performance. expectation our the overall will the reflect key these detail restructuring quarter. and with and months two from for in With our year moment,
by We we a in $XX.X net million million. total loss of quarter of and GAAP products a growth. $XXX million loss the net generated non-GAAP solid of $X performance reflecting revenues recorded year-over-year driven proprietary During our unit
the our increased year-over-year results XXXX, underlying reflecting line of million, contribution to QX net was units. in we by X% an to in gross from $XX.X offset compared adjustments in unit growth to to driven partially that XX.X% provided XX% the During increased expectation Medicaid net that XX.X% $XX of by were VIVITROL XXXX that with QX approximately These million call. quarter sales earnings primarily on QX increased
the in approximately decrease to QX we impacted primarily with Medicaid net QX. flat two gross QX years, last was in sales that of driven in favorably from seen from were the net data utilization due Consistent The by that by $X states to net XXXX as various VIVITROL adjustments sales we've sequential pattern last to highlighted fluctuations units X% million approximately quarter.
top quarter. VIVITROL sales our third concentrated net with in remained the [ph] of XX% states volume five representing
state We level growth states more year-over-year have have greater than continued growth. at efforts unit than to the our demonstrated and XX XX% diversify
range to $XXX year our we As we approach million. $XXX today, year expectation VIVITROL for to net of the million a end narrowing the sales are of the of full
from while see we product been net be Turning growth believe previous those $XXX and updating ARISTADA traction sales today efforts beginning are year a over $XXX to introduced slower for anticipated. a $XXX family, range expectation productive they'll to we to million our million. $XXX of to than the drive to gain XXXX million XXXX continue million to In range time, a ARISTADA number and we're ARISTADA has we of initiatives to this growth of
XX% growth. expectation QX, driven primarily months $XX.X XX%, to XX.X% quarter the for XX% demonstrated unit driven net consistent data for ARISTADA and year-over-year third to million, said, that growth. the our of full-year net growth net sales sales total nets. for ARISTADA year-over-year Underlying for second prescription of unit solid ARISTADA to quarter Gross by by with increased terms adjustments also in increased of gross Sequentially for therapy. were With
therapy to terms share market increase. new Against of atypical has was XX% September ARISTADA's the market and ARISTADA's long-acting X% months XXXX. also in in the September also backdrop in long-acting overall terms at XXXX. to market XX% of for share to And of September in XXXX a of grow compared Aripiprazole therapy September market continued ARISTADA's prescriptions prescriptions antipsychotics, has X% in new compared continued share that in XXXX, market to also double-digit months market long-acting rates, for of was the for
Moving franchise in royalty in following reflecting to quarter to $XXX.X in of we prior $XXX.X decline our AMPYRA compared $XX entering XXXX. competition revenues manufacturing the in the million on U.S. revenues million third from and generic a business, market year, our AMPYRA/FAMPYRA the million saw
Notably, $XX.X and sales year-over-year fewer market INVEGA by were Revenues batches and TRINZA of our INVEGA growth CONSTA, TRINZA at expiration CONSTA despite offset in end the manufacturing increased year. royalty SUSTENNA remained SUSTENNA INVEGA overall our for as INVEGA from quarter. RISPERDAL SUSTENNA royalties INVEGA the SUSTENNA million X.X% the RISPERDAL continued during of U.S. patent in of and TRINZA fairly this INVEGA May flat in
recognized revenues net our Alkermes will of driven we payment to The primarily reimbursement $XX.X Biogen trigger of VUMERITY sales prepares launch. revenue R&D of license look in expect with for mid we third that related the to for we expenses record teens it VUMERITY million, milestone on approval FDA VUMERITY Biogen. our will quarter development working results. by million receive collaboration $XXX to In royalty and forward QX as with commercial as of the
In expected expenses, for third operating various lower implementation total terms of than the following our were saving quarter cost expenses initiatives. of
was third expense in as in for ARISTADA we quarter support expenses compared both year for $XXX.X prior investments compared year in $XXX.X million of commercial quarter increased clinical for to million R&D prior XXXX. were for third the ALKS VIVITROL. $XXX.X the development SG&A the Our our million $XXX.X the organization and investment the to million of reflecting
approximately million at $XXX in $XXX with cash ended million the second at the we sheet, million approximately quarter of quarter. the end was The balance to third and outstanding our total total debt to Turning company's compared $XXX the of the end quarter. investments third approximately
update Let a me for XXXX. shift for broader to financial our now expectations
of the narrow of the Now year, way expectations. we're able that the provided through quarters three our we're ranges previously to
we morning. in expectations Our the outlined this full are issued earlier release press financial
range offset For sales line to net higher SUSTENNA expectation XXXX. in decrease than $X.XX expect continue be for $X.XX the the total expected revenues ARISTADA as INVEGA the royalties billion to to in we in top our of
cost early For we and our we our our review in quarter approximately savings cost operating Predominantly XXXX. as of the expense result begin initiated expenses organization. by of implement third decreased across structure operating $XX this, a line to the in the measures million items,
this our $XXX in for guidance million. reflected primarily our expense to to $XXX R&D is million In million terms $XXX XXXX million $XXX a the expectation the in to of expectation previous of decrease of from for range for XXXX
record $XX million and that quarter narrowed will a to SG&A expectation We our to $XXX a in to restructuring $XXX results. of also million expect fourth charge million GAAP the full-year range impact approximately XXXX our of for
financial we're that million range previous earnings the in the expectation GAAP loss million. and of As a net net expectations result of $XX this issued in for that million $XX call is from XXXX to for non-GAAP $XX expectation income range increasing unchanged, million the to $XX be but our the highlighted to the our updated I've are morning, for in release outlined today of press
the reducing our to as of improve areas open headcount Turning cost to number number including positions of functional re-projecting three years, spend. key our we reducing the hiring and our financial evaluated identified the restructuring, a streamlining we areas efficiency; current next external structure, the several across for plans organization, within
with to million R&D by related two We $XXX savings expect roughly approximately this one SG&A. deliver third driven restructuring of thirds to and
will earnings detailed our call for in February. more year-end on We provide financial expectations XXXX
savings the total achieve several an next capture Over basis. on us few ongoing to helping million non-GAAP to hundred sustained dollars years expect profitability we of
well-positioned believe cost for high levels. program incremental We what like we to XXXX and invest our structure at ALKS that the do our launch this been and lower ability we in development our the objective key restructuring has preserving now most be potential investment appropriately The ALKS are recalibrated this was opportunities, with to that of XXXX. to value believe significantly
development We expand business pursue our pipeline. our to that also increased to opportunities have have potential may the development flexibility
actively managing and in business pipeline to non-GAAP growth We profitability. advance our sustained in commercial our CNS are the achieve and are and development drive both portfolio, well-positioned candidates immuno-oncology
call Richard. the turn I'll that, With back to
